Buprenorphine (Suboxone, Sublocade) prior authorization at Centene

The PA criteria you'll need to meet

Centene reviews Buprenorphine (Suboxone, Sublocade) prior authorizations against its medical policy . Centene-specific context: Largest Medicaid MCO in US. Markets under Ambetter (ACA), Wellcare (MA), and state-specific Medicaid brands. State-specific appeal processes vary; check state Medicaid handbook.

Documentation packet checklist

• Chart note with diagnosis (ICD-10 code) and clinical severity markers
• Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
• Prior treatment history including dosing, duration, and reason for discontinuation
• Relevant labs, imaging, or assessment scores supporting medical necessity
• Prescriber attestation linking the FDA-approved indication to the patient's presentation
• Centene's medical policy URL referenced in the cover letter

Centene's common denial patterns

Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:

• Marketplace network adequacy issues
• Medicaid step therapy
• Specialty drug exclusions

Buprenorphine (Suboxone, Sublocade)-specific denial patterns and context

Across payers (not just Centene), Buprenorphine (Suboxone, Sublocade)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:

• Step therapy requiring sublingual before long-acting injectable
• Specialty pharmacy restriction
• Frequency reduction

Marketed as Suboxone, Subutex (sublingual), Sublocade (monthly injectable), Brixadi (weekly/monthly injectable). Federal Medicaid required coverage.

Manufacturer patient-assistance program: Indivior INSUPPORT — relevant when a Centene denial sticks and the patient needs bridge access while appealing.

How Centene approaches Medications for Opioid Use Disorder (MOUD) PAs

Centene's Medications for Opioid Use Disorder (MOUD) reviewer typically anchors Buprenorphine prior-auth decisions on specialty drug exclusions. Pharmacy-benefit review for Buprenorphine at Centene is routed through Envolve Pharmacy Solutions / state-specific Medicaid PBMs. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 60-day internal-appeal window begins from the denial date. MHPAEA non-quantitative-treatment-limitation analysis applies — request Centene's written NQTL comparative analysis under the 2023 final rule when the MOUD denial appears stricter than comparable medical-side prior auth. Centene is domiciled in MO, so unresolved appeals escalate to the MO insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Largest Medicaid MCO in US.

If the PA is denied

Centene gives prescribers and members 60 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://ambetterhealth.com/provider-resources) with the same packet plus a peer-reviewed citation supporting Buprenorphine (Suboxone, Sublocade)for the patient's indication.

Medicare Advantage path: if Centene misses the appeal deadline the case auto-forwards to the Independent Review Entity (Maximus). Time-to-decision favors clinicians who request expedited review with a 72-hour clock when the delay risks harm.

Centene as a Medicare Advantage organization operates under 42 CFR Part 422 Subpart D for organization determinations: a standard (non-urgent) pre-service decision is due within 7 calendar days under CMS-0057-F (effective January 1, 2026; reduced from the prior 14-day standard), an expedited decision within 72 hours, and Part B drug decisions within 72 hours under the 2023 step-therapy rule extension. For Buprenorphine, the Part B vs Part D coverage determination is the threshold question — Part B drugs (provider-administered) follow the organization-determination track under 42 CFR §422.566, while Part D drugs follow the coverage-determination track under 42 CFR §423.566. Missed deadlines auto-forward to the Independent Review Entity (Maximus Federal Services) without member action — track the calendar carefully because this is the most reliable lever in MA appeals.

Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Centene denial on DenialHelp.

Contact Centene

• Provider portal: https://ambetterhealth.com/provider-resources